Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst ...

Dianthus Therapeutics is offering Nanjing Leads Biolabs up to $1 billion biobucks for licensing rights to a bispecific antibody designed to treat certain autoimmune disorders. Under the terms of the ...

The Drug Information Association (DIA) today announced the launch of DIA ASCENT, a new global platform designed to support early-stage biotechnology drug development innovation, along with its ...

US biotech Moderna today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2026 with a focus on growing sales, launching new infectious disease products and ...

Crescent Biopharma shares rose in premarket trading Thursday after announcing a Kelun‑Biotech partnership and new pipeline developments, which include three programs slated for 2026 trials. Shares ...

Chai Discovery has just vaulted into the biotech big leagues, securing a $130 million Series B round that values the company at $1.3 billion and signals how aggressively artificial intelligence is ...

Krystal Biotech is upgraded to Strong Buy as Vyjuvek sales surge and catalysts build. Click here to know more.

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

More than a year and a half into Cullinan Therapeutics’ pivot from an oncology company to a hybrid autoimmune player, the biotech is parting ways with a pair of cancer programs. The move balances the ...

A University of Bradford‑supported biotech start‑up has been selected for a flagship Innovate UK‑funded programme.

As artificial intelligence continues to redefine industries, its most transformative impact in biotech is happening behind the scenes, where accuracy, explainability, and compliance matter most.